Post by OncoAlert

This #WeekInOncology by @OncoAlert| GU Edition 🚨 Today, our GU Faculty Dr. Natalia Gandur 🇦🇷 reviews the LITESPARK-022 trial, led by OncoAlert Faculty member Dr. Toni K. Choueiri.🇺🇸 📄 Adjuvant Pembrolizumab plus Belzutifan for Renal-Cell Carcinoma NEJM, July 1, 2026 LINK👉 https://buff.ly/JYWJXfr The phase 3 trial showed that adding the HIF-2α inhibitor belzutifan to adjuvant pembrolizumab after nephrectomy significantly improved disease-free survival in high-risk clear-cell RCC. 🔬 Key results: ➡️ DFS benefit: HR 0.72 (95% CI, 0.59–0.87; P<0.001) ➡️ 24-month DFS: 80.7% vs 73.7% ➡️ No significant OS difference at interim analysis ➡️ Higher grade ≥3 toxicities with combination therapy (52.1% vs 30.2%) 🎥 Watch Dr. Gandur’s expert discussion on this important advance in GU oncology. #KidneyCancer #GUOncology #RenalCellCarcinoma #Oncology #Immunotherapy #OncoAlert Toni Choueiri Robert Motzer Jose A. Karam, MD, FACS Wesley Yip Christian Caglevic Roberto Iacovelli Yüksel ÜRÜN Elena Verzoni Juan C Vazquez Limon Camillo Porta Robert Uzzo, MD, MBA, FACS Jae Lyun Lee Balaji Venugopal Rana McKay Hans Hammers Jad Chahoud, MD, MPH-MHA Hong Liu Joseph Burgents, PhD Manish Kumar Sharma Tom Powles Sumanta Pal, MD, FASCO Andrea Apolo Neeraj Agarwal, MD, FASCO Petros Grivas Tian Zhang Ravindran Kanesvaran Prof. Dr. Axel S. Merseburger Guru Sonpavde, MD Enrique Grande Daniel Castellano David Braun Brian Rini Dr. María Natalia Gandur Quiroga Sara Coca Membribes Amanda Nizam Advanced Urologic Cancer Consensus Conference

Video Content